SVCM
PCVX icon

Saturn V Capital Management’s Vaxcyte PCVX Stock Holding History

Saturn V Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.6M Buy
852,914
+28,382
+3% +$1.54M 7.11% 4
2026
Q1 		$47.9M Buy
824,532
+25,592
+3% +$1.39M 8.68% 4
2025
Q4 		$36.9M Buy
798,940
+10,499
+1% +$470K 6.77% 5
2025
Q3 		$28.4M Buy
788,441
+244,220
+45% +$8.09M 6.23% 6
2025
Q2 		$17.7M Buy
544,221
+311,926
+134% +$10.2M 7.17% 4
2025
Q1 		$8.77M Buy
232,295
+28,010
+14% +$2.24M 4.43% 10
2024
Q4 		$16.7M Sell
204,285
-702
-0.3% -$69.7K 6.55% 5
2024
Q3 		$23.4M Sell
204,987
-10,693
-5% -$964K 8.37% 3
2024
Q2 		$16.3M Buy
215,680
+30,505
+16% +$2.08M 6.15% 4
2024
Q1 		$12.6M Buy
+185,175
New +$12.8M 5.07% 9

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Saturn V Capital Management's PCVX Position: Q2 2026 in Review

Saturn V Capital Management increased its Vaxcyte (PCVX) stake by 3.4% in Q2 2026, buying an estimated $1.54M and bringing the position to 852,914 shares worth $49.6M. The position accounts for 7.11% of the portfolio, ranked #4.

Saturn V Capital Management first reported a position in PCVX in Q1 2024 and has held it in 10 quarters since. 332 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Saturn V Capital Management held 852,914 shares of Vaxcyte worth $49.6M as of Q2 2026.
  • Saturn V Capital Management bought 28,382 Vaxcyte shares in Q2 2026, an estimated $1.54M.
  • Vaxcyte made up 7.11% of Saturn V Capital Management's portfolio in Q2 2026, its #4 holding.
  • Saturn V Capital Management first reported a position in Vaxcyte in Q1 2024 and has held it in 10 quarters since.
  • 332 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Saturn V Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.